Paxlovid (nirmatrelvir/ritonavir) and Lagevrio (molnupiravir) are the primary FDA-authorized antiviral treatments used to prevent hospitalization and death in high-risk COVID-19 patients. According to the U.S. Food and Drug Administration (FDA), Paxlovid is generally the preferred first-line treatment due to higher efficacy, while Lagevrio serves as an alternative for patients with specific contraindications.
The deployment of these antivirals marked a shift in pandemic management from supportive care to targeted viral inhibition. Both drugs target the virus’s ability to replicate, but they use different biological mechanisms to achieve this goal. The FDA currently authorizes these treatments for adults who have mild-to-moderate COVID-19 but are at high risk for progression to severe disease.
How does Paxlovid work to prevent severe COVID-19?
Paxlovid combines two medications: nirmatrelvir, which stops the virus from replicating, and ritonavir, which slows the breakdown of nirmatrelvir in the body. This combination inhibits the 3CL protease, an enzyme the SARS-CoV-2 virus needs to process proteins and create new viral particles. According to data from the EPIC-HR clinical trial published in the New England Journal of Medicine, Paxlovid reduced the risk of COVID-19-related hospitalization or death by approximately 89% when administered within three days of symptom onset.
The drug is administered as a five-day course of oral tablets. The FDA notes that Paxlovid is effective across various Omicron subvariants because it targets a highly conserved part of the viral protease that does not mutate as quickly as the spike protein.
When is Lagevrio used instead of Paxlovid?
Lagevrio is typically prescribed when Paxlovid is not a viable option. This often happens if a patient has severe kidney disease or takes medications that interact dangerously with ritonavir. Unlike Paxlovid, Lagevrio (molnupiravir) is a nucleoside analogue. It works by introducing “errors” into the viral genetic code during replication, eventually making the virus non-functional. This process is known as viral mutagenesis.
The efficacy of Lagevrio is lower than that of Paxlovid. The PANORAMIC trial, as reported by the National Institutes of Health (NIH), found that molnupiravir reduced the risk of hospitalization or death by about 30% in unvaccinated adults. Because of this lower efficacy, the NIH COVID-19 Treatment Guidelines suggest Lagevrio as a second- or third-line option.
What are the risks and drug interactions for these antivirals?
Drug-drug interactions are the primary concern with Paxlovid. The ritonavir component inhibits the CYP3A enzyme in the liver, which processes many common medications. According to the FDA, this can lead to dangerously high levels of other drugs in the bloodstream, including certain statins, blood thinners, and anti-seizure medications. Physicians must conduct a full medication review before prescribing Paxlovid.
Lagevrio carries different restrictions. The FDA warns against using molnupiravir during pregnancy due to potential fetal harm. While it has fewer drug-drug interactions than Paxlovid, its ability to induce mutations in the virus has led to ongoing monitoring by health agencies to ensure it doesn’t contribute to the emergence of new viral variants.
Paxlovid vs. Lagevrio: Comparison at a Glance
The following table compares the two primary antiviral options based on FDA and NIH data.
| Feature | Paxlovid (Nirmatrelvir/Ritonavir) | Lagevrio (Molnupiravir) |
|---|---|---|
| Mechanism | Protease Inhibitor | Viral Mutagenesis |
| Efficacy | High (~89% reduction in severe outcomes) | Moderate (~30% reduction in severe outcomes) |
| Primary Risk | Significant drug-drug interactions | Contraindicated in pregnancy |
| Preferred Use | First-line for high-risk adults | Alternative when Paxlovid is contraindicated |
How are these drugs administered and timed?
Timing is critical for both treatments. The FDA specifies that both Paxlovid and Lagevrio must be started within five days of symptom onset to be effective. Once the virus has triggered a systemic inflammatory response—often seen in later stages of the disease—these antivirals are less effective because the damage is driven by the immune system rather than viral replication.
Paxlovid is taken twice daily for five days. Lagevrio is also taken for five days, though the dosage frequency differs. Both are oral medications, making them more accessible than intravenous treatments like remdesivir, which requires a clinical setting for administration.
Ongoing research focuses on combination therapies and the development of “protease-sparing” antivirals that provide the efficacy of Paxlovid without the drug-interaction risks associated with ritonavir. Public health agencies continue to emphasize that these treatments are supplements to, not replacements for, vaccination and boosters.